Related references
Note: Only part of the references are listed.Sacubitril and valsartan protect from experimental myocardial infarction by ameliorating oxidative damage in Wistar rats
Mohd Imran et al.
CLINICAL AND EXPERIMENTAL HYPERTENSION (2019)
The combination of a neprilysin inhibitor (sacubitril) and angiotensin-II receptor blocker (valsartan) attenuates glomerular and tubular injury in the Zucker Obese rat
Javad Habibi et al.
CARDIOVASCULAR DIABETOLOGY (2019)
Discharge treatment with angiotensin-converting enzyme inhibitor/angiotensin receptor blocker after a heart failure hospitalisation is associated with a better prognosis irrespective of left ventricular ejection fraction
Lourdes Vicent et al.
INTERNAL MEDICINE JOURNAL (2019)
Angiotensin Receptor Neprilysin Inhibitor Attenuates Myocardial Remodeling and Improves Infarct Perfusion in Experimental Heart Failure
Daniel PFau et al.
SCIENTIFIC REPORTS (2019)
Effects of sacubitril/valsartan on neprilysin targets and the metabolism of natriuretic peptides in chronic heart failure: a mechanistic clinical study
Helene Nougue et al.
EUROPEAN JOURNAL OF HEART FAILURE (2019)
Sacubitril/valsartan therapeutic strategy in HFpEF: Clinical insights and perspectives
Mauro Gori et al.
INTERNATIONAL JOURNAL OF CARDIOLOGY (2019)
Natriuretic peptides in heart failure: Current achievements and future perspectives
Massimo Volpe et al.
INTERNATIONAL JOURNAL OF CARDIOLOGY (2019)
Angiotensin-Neprilysin Inhibition in Acute Decompensated Heart Failure
Eric J. Velazquez et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Synergy between sacubitril and valsartan leads to hemodynamic, antifibrotic, and exercise tolerance benefits in rats with preexisting heart failure
Mikhail Y. Maslov et al.
AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY (2019)
Impact of systolic blood pressure on the safety and tolerability of initiating and up-titrating sacubitril/valsartan in patients with heart failure and reduced ejection fraction: insights from the TITRATION study
Michele Senni et al.
EUROPEAN JOURNAL OF HEART FAILURE (2018)
Baseline Characteristics of Patients With Heart Failure and Preserved Ejection Fraction in the PARAGON-HF Trial
Scott D. Solomon et al.
CIRCULATION-HEART FAILURE (2018)
Vascular and Neural Complications in Type 2 Diabetic Rats: Improvement by Sacubitril/Valsartan Greater Than Valsartan Alone
Eric P. Davidson et al.
DIABETES (2018)
LCZ696 (Sacubitril/Valsartan), an Angiotensin-Receptor Neprilysin Inhibitor, Attenuates Cardiac Hypertrophy, Fibrosis, and Vasculopathy in a Rat Model of Chronic Kidney Disease
Yasunori Suematsu et al.
JOURNAL OF CARDIAC FAILURE (2018)
Effects of dual angiotensin type 1 receptor/neprilysin inhibition vs. angiotensin type 1 receptor inhibition on target organ injury in the stroke-prone spontaneously hypertensive rat
Speranza Rubattu et al.
JOURNAL OF HYPERTENSION (2018)
Sacubitril/Valsartan Averts Adverse Post-Infarction Ventricular Remodeling and Preserves Systolic Function in Rabbits
Juan Torrado et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2018)
Improved Insulin Sensitivity With Angiotensin Receptor Neprilysin Inhibition in Individuals With Obesity and Hypertension
J. Jordan et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2017)
Effects of Sacubitril/Valsartan Versus Olmesartan on Central Hemodynamics in the Elderly With Systolic Hypertension The PARAMETER Study
Bryan Williams et al.
HYPERTENSION (2017)
Global, Regional, and National Burden of Cardiovascular Diseases for 10 Causes, 1990 to 2015
Gregory A. Roth et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2017)
Angiotensin II Receptor-Neprilysin Inhibitor Sacubitril/Valsartan Improves Endothelial Dysfunction in Spontaneously Hypertensive Rats
Takunori Seki et al.
JOURNAL OF THE AMERICAN HEART ASSOCIATION (2017)
Effect of sacubitril/valsartan versus enalapril on glycaemic control in patients with heart failure and diabetes: a post-hoc analysis from the PARADIGM-HF trial
Jelena P. Seferovic et al.
LANCET DIABETES & ENDOCRINOLOGY (2017)
Efficacy and Safety of Sacubitril/Valsartan (LCZ696) Compared With Olmesartan in Elderly Asian Patients (≥ 65 Years) With Systolic Hypertension
Ouppatham Supasyndh et al.
AMERICAN JOURNAL OF HYPERTENSION (2017)
The evolution of natriuretic peptide augmentation in management of heart failure and the role of sacubitril/valsartan
Srikanth Yandrapalli et al.
ARCHIVES OF MEDICAL SCIENCE (2017)
2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America
Clyde W. Yancy et al.
CIRCULATION (2017)
The effects of sacubitril/valsartan on coronary outcomes in PARADIGM-HF
Ulrik M. Mogensen et al.
AMERICAN HEART JOURNAL (2017)
Heart Disease and Stroke Statistics-2016 Update A Report From the American Heart Association
Dariush Mozaffarian et al.
CIRCULATION (2016)
Plasma Biomarkers Reflecting Profibrotic Processes in Heart Failure With a Preserved Ejection Fraction Data From the Prospective Comparison of ARNI With ARB on Management of Heart Failure With Preserved Ejection Fraction Study
Michael R. Zile et al.
CIRCULATION-HEART FAILURE (2016)
Risk Related to Pre-Diabetes Mellitus and Diabetes Mellitus in Heart Failure With Reduced Ejection Fraction Insights From Prospective Comparison of ARNI With ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure Trial
Soren L. Kristensen et al.
CIRCULATION-HEART FAILURE (2016)
Blood pressure-independent renoprotection in diabetic rats treated with AT1 receptor-neprilysin inhibition compared with AT1 receptor blockade alone
Lodi C. W. Roksnoer et al.
CLINICAL SCIENCE (2016)
LCZ696, an angiotensin receptor-neprilysin inhibitor, improves cardiac function with the attenuation of fibrosis in heart failure with reduced ejection fraction in streptozotocin-induced diabetic mice
Yasunori Suematsu et al.
EUROPEAN JOURNAL OF HEART FAILURE (2016)
2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC
Piotr Ponikowski et al.
EUROPEAN JOURNAL OF HEART FAILURE (2016)
Myocardial Microvascular Inflammatory Endothelial Activation in Heart Failure With Preserved Ejection Fraction
Constantijn Franssen et al.
JACC-HEART FAILURE (2016)
LCZ696, Angiotensin II Receptor-Neprilysin Inhibitor, Ameliorates High-Salt-Induced Hypertension and Cardiovascular Injury More Than Valsartan Alone
Hiroaki Kusaka et al.
AMERICAN JOURNAL OF HYPERTENSION (2015)
Renal effects of the angiotensin receptor neprilysin inhibitor LCZ696 in patients with heart failure and preserved ejection fraction
Adriaan A. Voors et al.
EUROPEAN JOURNAL OF HEART FAILURE (2015)
B-Type Natriuretic Peptide Deletion Leads to Progressive Hypertension, Associated Organ Damage, and Reduced Survival Novel Model for Human Hypertension
Sara J. Holditch et al.
HYPERTENSION (2015)
Optimum AT1 receptor-neprilysin inhibition has superior cardioprotective effects compared with AT1 receptor blockade alone in hypertensive rats
Lodi C. W. Roksnoer et al.
KIDNEY INTERNATIONAL (2015)
ANP-induced signaling cascade and its implications in renal pathophysiology
Franziska Theilig et al.
AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY (2015)
Angiotensin Receptor Neprilysin Inhibition Compared With Enalapril on the Risk of Clinical Progression in Surviving Patients With Heart Failure
Milton Packer et al.
CIRCULATION (2015)
Effects of Neutral Endopeptidase (Neprilysin) Inhibition on the Response to Other Vasoactive Peptides in Small Human Resistance Arteries: Studies with Thiorphan and Omapatrilat
Jonathan R. Dalzell et al.
CARDIOVASCULAR THERAPEUTICS (2014)
Independence of the blood pressure lowering effect and efficacy of the angiotensin receptor neprilysin inhibitor, LCZ696, in patients with heart failure with preserved ejection fraction: an analysis of the PARAMOUNT trial
Pardeep S. Jhund et al.
EUROPEAN JOURNAL OF HEART FAILURE (2014)
Angiotensin-Neprilysin Inhibition versus Enalapril in Heart Failure
John J. V. McMurray et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Neutral endopeptidase inhibition and the natriuretic peptide system: an evolving strategy in cardiovascular therapeutics
Sarah Mangiafico et al.
EUROPEAN HEART JOURNAL (2013)
Atrial natriuretic peptide and regulation of vascular function in hypertension and heart failure: implications for novel therapeutic strategies
Speranza Rubattu et al.
JOURNAL OF HYPERTENSION (2013)
Low Myocardial Protein Kinase G Activity in Heart Failure With Preserved Ejection Fraction
Loek van Heerebeek et al.
CIRCULATION (2012)
The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial
Scott D. Solomon et al.
LANCET (2012)
Angiotensin Converting Enzyme 2, Angiotensin-(1-7), and Receptor Mas Axis in the Kidney
Sergio Veloso Brant Pinheiro et al.
INTERNATIONAL JOURNAL OF HYPERTENSION (2012)
Endothelin
Yoshifumi Kawanabe et al.
CELLULAR AND MOLECULAR LIFE SCIENCES (2011)
Natriuretic peptide metabolism, clearance and degradation
Lincoln R. Potter
FEBS JOURNAL (2011)
Pharmacokinetics and Pharmacodynamics of LCZ696, a Novel Dual-Acting Angiotensin Receptor-Neprilysin Inhibitor (ARNi)
Jessie Gu et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2010)
NPR-C: a component of the natriuretic peptide family with implications in human diseases
Speranza Rubattu et al.
JOURNAL OF MOLECULAR MEDICINE-JMM (2010)
Blood-pressure reduction with LCZ696, a novel dual-acting inhibitor of the angiotensin II receptor and neprilysin: a randomised, double-blind, placebo-controlled, active comparator study
Luis Miguel Ruilope et al.
LANCET (2010)
Regional clearance of amino-terminal pro-brain natriuretic peptide from human plasma
Suetonia C. Palmer et al.
EUROPEAN JOURNAL OF HEART FAILURE (2009)
Structural Substrate Conditions Required for Neutral Endopeptidase-Mediated Natriuretic Peptide Degradation
Kristin Pankow et al.
JOURNAL OF MOLECULAR BIOLOGY (2009)
Dipeptidyl peptidase IV in angiotensin-converting enzyme inhibitor-associated angioedema
James Brian Byrd et al.
HYPERTENSION (2008)
Signaling cascade that mediates endothelial nitric oxide synthase activation induced by atrial natriuretic peptide
Rosana Elesgaray et al.
REGULATORY PEPTIDES (2008)
Role of NPR-C natriuretic receptor in nitric oxide system activation induced by atrial natriuretic peptide
Maria Angeles Costa et al.
REGULATORY PEPTIDES (2006)
Neutral endopeptidase 24.11 and dipeptidyl peptidase IV are both mediators of the degradation of glucagon-like peptide 1 in the anaesthetised pig
A Plamboeck et al.
DIABETOLOGIA (2005)
Vascular actions of natriuretic peptides - Cyclic GMP-dependent and -independent mechanisms
A Ahluwalia et al.
BASIC RESEARCH IN CARDIOLOGY (2004)
Cardioprotective functions of atrial natriuretic peptide and B-type natriuretic peptide: A brief review
RL Woods
CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY (2004)
Vasopeptidase inhibitor omapatrilat induces profound insulin sensitization and increases myocardial glucose uptake in Zucker fatty rats - Studies comparing a vasopeptidase inhibitor, angiotensin-converting enzyme inhibitor, and angiotensin II type I receptor blocker
CH Wang et al.
CIRCULATION (2003)
Comparison of omapatrilat chronic and enalapril in patients with heart failure - The omapatrilat versus enalapril randomized trial of utility in reducing events (OVERTURE)
M Packer et al.
CIRCULATION (2002)
Neprilysin inhibitors potentiate effects of bradykinin on B2 receptor
PA Deddish et al.
HYPERTENSION (2002)
A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure
JN Cohn et al.
NEW ENGLAND JOURNAL OF MEDICINE (2001)
Adrenomedullin (ADM) in the human forearm vascular bed:: effect of neutral endopeptidase inhibition and comparison with proadrenomedullin NH2-terminal 20 peptide (PAMP)
IB Wilkinson et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2001)
ANP in regulation of arterial pressure and fluid-electrolyte balance: lessons from genetic mouse models
LG Melo et al.
PHYSIOLOGICAL GENOMICS (2000)
Cardiac fibrosis in mice lacking brain natriuretic peptide
N Tamura et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2000)
Share Paper
